NCT05315180 - A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Malignant NeoplasmsMetastatic Cancer

Interventions

DRUG

BPI-421286

Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation

Trial Locations (5)

RECRUITING

Shun Lu, Ph.D, Shanghai

RECRUITING

Shun Lu, Ph.D, Shanghai

RECRUITING

Wen Li, Ph.D, Hangzhou

RECRUITING

Yun Fan,Ph.D, Hangzhou

RECRUITING

Dingzhi Huang, Ph.D, Tianjin